eamdacademy.org-wX6g-1789518388-r683742261 1789518388 Eurasian Academy of Medicine and Dentistry info@eamdacademy.org Eurasian Academy of Medicine and Dentistry Journal of Applied Pharmaceutical Technologies and Systems J Appl Pharm Technol Syst 3149-9589 2024 3 2 Ravi Kumar Neha Sharma Aniket Deshmukh Arjun Nair Meera Pillai 2024 10.68159/r683742261 https://eamdacademy.org/pub/journal/3/article/r683742261 Zarmpi P, Flanagan T, Meehan E, Mann J, Fotaki N. Biopharmaceutical aspects and implications of excipient variability in drug product performance. Eur J Pharm Biopharm. 2017;111:1-5. Indulkar AS, Lou X, Zhang GGZ, Taylor LS. Insights into the dissolution mechanism of ritonavir-copovidone amorphous solid dispersions: importance of congruent release for enhanced performance. Mol Pharm. 2019;16(3):1327-39. Alskar LC, Keemink J, Johannesson J, Porter CJH, Bergström CAS. Impact of drug physicochemical properties on lipolysis-triggered drug supersaturation and precipitation from lipid-based formulations. Mol Pharm. 2018;15(10):4733-44. Elkhabaz A, Sarkar S, Dinh JK, Simpson GJ, Taylor LS. Variation in supersaturation and phase behavior of ezetimibe amorphous solid dispersions upon dissolution in different biorelevant media. Mol Pharm. 2018;15(1):193-206. Suys EJ, Brundel DH, Chalmers DK, Pouton CW, Porter CJH. Interaction with biliary and pancreatic fluids drives supersaturation and drug absorption from lipid-based formulations of low (saquinavir) and high (fenofibrate) permeability poorly soluble drugs. J Control Release. 2021;331:45-61. Yang R, Mann AK, Van Duong T, Ormes JD, Okoh GA, Hermans A, et al. Drug release and nanodroplet formation from amorphous solid dispersions: insight into the roles of drug physicochemical properties and polymer selection. Mol Pharm. 2021;18(5):2066-81. Price DJ, Ditzinger F, Koehl NJ, Jankovic S, Tsakiridou G, Nair A, et al. Approaches to increase mechanistic understanding and aid in the selection of precipitation inhibitors for supersaturating formulations—a PEARRL review. J Pharm Pharmacol. 2019;71(4):483-509. Forbes TP, Gillen JG, Feeney W, Ho J. Quality by design considerations for drop-on-demand point-of-care pharmaceutical manufacturing of precision medicine. Mol Pharm. 2024;21(7):3268-80. Zarmpi P, Flanagan T, Meehan E, Mann J, Fotaki N. Biopharmaceutical understanding of excipient variability on drug apparent solubility based on drug physicochemical properties. Case study: superdisintegrants. AAPS J. 2020;22(2):46. Zarmpi P, Flanagan T, Meehan E, Mann J, Fotaki N. Impact of magnesium stearate presence and variability on drug apparent solubility based on drug physicochemical properties. AAPS J. 2020;22(4):75. Saboo S, Kestur US, Flaherty DP, Taylor LS. Congruent release of drug and polymer from amorphous solid dispersions: insights into the role of drug-polymer hydrogen bonding, surface crystallization, and glass transition. Mol Pharm. 2020;17(4):1261-75. Lu X, Li M, Huang C, Lowinger MB, Xu W, Yu L, et al. Atomic-level drug substance and polymer interaction in posaconazole amorphous solid dispersion from solid-state NMR. Mol Pharm. 2020;17(7):2585-98. Milliken RL, Quinten T, Andersen SK, Lamprou DA. Application of 3D printing in early phase development of pharmaceutical solid dosage forms. Int J Pharm. 2024;653:123902. Muehlenfeld C, Duffy P, Yang F, Zermeño Pérez D, El-Saleh F, Durig T. Excipients in pharmaceutical additive manufacturing: a comprehensive exploration of polymeric material selection for enhanced 3D printing. Pharmaceutics. 2024;16(3):317. Bapat P, Paul S, Tseng YC, Taylor LS. Interplay of drug-polymer interactions and release performance for HPMCAS-based amorphous solid dispersions. Mol Pharm. 2024;21(3):1466-78. Coutinho AL, Hom K, Polli JE. Prediction of successful amorphous solid dispersion pairs through liquid-state nuclear magnetic resonance. Mol Pharm. 2024;21(12):6153-65. Higginbotham T, Meier K, Ramírez J, Garaizar A. Predicting drug-polymer compatibility in amorphous solid dispersions by MD simulation: on the trap of solvation free energies. Mol Pharm. 2025;22(2):760-70. Shi C, Zhao H, Fang Y, Shen L, Zhao L. Lactose in tablets: functionality, critical material attributes, applications, modifications and co-processed excipients. Drug Discov Today. 2023;28(9):103696. Janssen PH, Fathollahi S, Dickhoff BH, Frijlink HW. Critical review on the role of excipient properties in pharmaceutical powder-to-tablet continuous manufacturing. Expert Opin Drug Deliv. 2024;21(7):1069-79. Anane-Adjei AB, Jacobs E, Nash SC, Askin S, Soundararajan R, Kyobula M, et al. Amorphous solid dispersions: utilization and challenges in preclinical drug development within AstraZeneca. Int J Pharm. 2022;614:121387. Petkov V, Vinarov Z, Tcholakova S. Mechanisms of dissolution and crystallization of amorphous glibenclamide. Int J Pharm. 2024;666:124820. Holm R, Kuentz M, Ilie-Spiridon AR, Griffin BT. Lipid-based formulations as supersaturating oral delivery systems: from current to future industrial applications. Eur J Pharm Sci. 2023;189:106556. Sirvi A, Janjal A, Guleria K, Chand M, Sangamwar AT. Thermally induced supersaturation approach for optimizing drug loading and biopharmaceutical properties of supersaturated lipid-based formulations: case studies with ibrutinib and enzalutamide. AAPS PharmSciTech. 2024;25(7):192. Jacobsen AC, Kabedev A, Sinko PD, Palm JE, Bergström CAS, Teleki A. Intrinsic lipolysis rate for systematic design of lipid-based formulations. Drug Deliv Transl Res. 2023;13(5):1288-304. Hiew TN, Zemlyanov DY, Taylor LS. Balancing solid-state stability and dissolution performance of lumefantrine amorphous solid dispersions: the role of polymer choice and drug-polymer interactions. Mol Pharm. 2022;19(2):392-413. Nora GI, Venkatasubramanian R, Strindberg S, Siqueira-Jørgensen SD, Pagano L, Romanski FS, et al. Combining lipid-based drug delivery and amorphous solid dispersions for improved oral drug absorption of a poorly water-soluble drug. J Control Release. 2022;349:206-12. Moseson DE, Tran TB, Karunakaran B, Ambardekar R, Hiew TN. Trends in amorphous solid dispersion drug products approved by the US Food and Drug Administration between 2012 and 2023. Int J Pharm X. 2024;7:100259.